(Q45369099)

English

Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy

scientific article published on 11 February 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Epstein–Barr virus

0 references

1 reference

based on heuristic

inferred from title

author name string

Xin An

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Feng-Hua Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Pei-Rong Ding

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Ling Deng

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Wen-Qi Jiang

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Li Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Jian-Yong Shao

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Yu-Hong Li

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

language of work or name

0 references

publication date

11 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

3750-3757

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

21 January 2018

Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

7 January 2021

based on heuristic

inferred from DOI database lookup

Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25932

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25932

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45369099&oldid=2075914582"